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Rationale: Pulmonary Alveolar Proteinosis (PAP) patients exhibit an acquired deficiency of biologically active
granulocyte-macrophage colony stimulating factor (GM-CSF) attributable to GM-CSF specific autoantibodies. PAP
alveolar macrophages are foamy, lipid-filled cells with impaired surfactant clearance and markedly reduced
expression of the transcription factor peroxisome proliferator-activated receptor gamma (PPARγ) and the
PPARγ-regulated ATP binding cassette (ABC) lipid transporter, ABCG1. An open label proof of concept Phase II
clinical trial was conducted in PAP patients using rituximab, a chimeric murine-human monoclonal antibody
directed against B lymphocyte specific antigen CD20. Rituximab treatment decreased anti-GM-CSF antibody levels
in bronchoalveolar lavage (BAL) fluid, and 7/9 patients completing the trial demonstrated clinical improvement as
measured by arterial blood oxygenation.
Objectives: This study sought to determine whether rituximab therapy would restore lipid metabolism in PAP
alveolar macrophages.
Methods: BAL samples were collected from patients pre- and 6-months post-rituximab infusion for evaluation of
mRNA and lipid changes.
Results: Mean PPARγ and ABCG1 mRNA expression increased 2.8 and 5.3-fold respectively (p≤ 0.05) after
treatment. Lysosomal phospholipase A2 (LPLA2) (a key enzyme in surfactant degradation) mRNA expression was
severely deficient in PAP patients pre-treatment but increased 2.8-fold post-treatment. In supplemental animal
studies, LPLA2 deficiency was verified in GM-CSF KO mice but was not present in macrophage-specific PPARγ KO
mice compared to wild-type controls. Oil Red O intensity of PAP alveolar macrophages decreased after treatment,
indicating reduced intracellular lipid while extracellular free cholesterol increased in BAL fluid. Furthermore, total
protein and Surfactant protein A were significantly decreased in the BAL fluid post therapy.
Conclusions: Reduction in GM-CSF autoantibodies by rituximab therapy improves alveolar macrophage lipid
metabolism by increasing lipid transport and surfactant catabolism. Mechanisms may involve GM-CSF stimulation of
alveolar macrophage ABCG1 and LPLA2 activities by distinct pathways.
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Surfactant catabolism is impaired in alveolar macro-
phages from patients with pulmonary alveolar proteino-
sis (PAP) and GM-CSF knock out (KO) mice. In the
GM-CSF KO mouse, the PAP like syndrome is revers-
ible by exogenous GM-CSF or local over-expression of
GM-CSF. Studies from GM-CSF KO mice initially sug-
gested that PAP might be due to idiopathic defects in
GM-CSF receptors or production [1]. In adults with
PAP, however, no mutations in GM-CSF receptor or
surfactant coding sequences have been described [2].
Moreover, studies from our lab and others reported that
both monocytes and alveolar macrophages from adult
PAP patients are able to produce and respond to GM-
CSF [3,4]. Evidence for adult PAP as an autoimmune
disease was first presented by Kitamura et al., who
noted that circulating anti-GM-CSF autoantibodies neu-
tralized GM-CSF biological activity, and thus resulted
in a virtual GM-CSF deficiency [5,6]. Subsequent stud-
ies in idiopathic adult PAP patients confirmed the exist-
ence of anti-GM-CSF antibodies and demonstrated that
autoantibody levels were clinically useful for diagnosis
[7-10].
Alveolar macrophages from both PAP patients and
GM-CSF KO mice display a striking deficiency in PPARγ
and in the lipid transporter ABCG1 [11,12]. GM-CSF
treatment increased ABCG1 expression in macrophages
in vitro and in alveolar macrophages of PAP patients
in vivo. Overexpression of PPARγ by lentivirus-PPARγ
transduction of primary human alveolar macrophages or
activation by rosiglitazone also increased ABCG1 ex-
pression [12]. In GM-CSF KO mice, in vivo treatment
with lentivirus-PPARγ increased both PPARγ and
ABCGI expression while reducing lipid accumulation in
the lung. More recently, we observed improved lung
function and reduced lipid accumulation in GM-CSF
KO mice treated in vivo with lentivirus-ABCG1 [13].
Collectively, these studies suggest that surfactant
accumulation in PAP alveolar macrophages stems from
GM-CSF deficiency leading to PPARγ deficiency and
subsequent reduction of ABCG1 expression.
Lung surfactant catabolism is also known to be
dependent upon lysosomal phospholipase A2 (LPLA2)
activity, an enzyme selectively expressed in alveolar
macrophages but not other tissue macrophages or circu-
lating monocytes [14]. LPLA2 activity is deficient in
GM-CSF KO mice but is restored by transgenic expres-
sion of GM-CSF [14]. Interestingly, in vitro studies pro-
vide no evidence of LPLA2 stimulation by PPARγ
although induction occurs through the PPARγ heterodi-
mer, retinoid X receptor (RXR) via stimulation by all-
trans-retinoic acid [15].
Rituximab, a chimeric murine-human monoclonal
antibody directed against CD20, a B lymphocyte-specificmembrane antigen, has been shown to deplete human B
cells in vivo [16]. Rituximab was approved by the Food
and Drug Administration in 1997 for treatment of CD20
(+) B cell lymphoma and has since been in use for B cell
malignancies. Subsequently, rituximab therapy was ap-
plied to treatment of autoimmune disease, and results
have shown clinical benefit in systemic lupus erythema-
tosus [17], rheumatoid arthritis [18], and Wegener’s
granulomatosis [19] among others.
Based upon data indicating autoantibody involve-
ment in PAP, we recently carried out the first
prospective, open label, proof of concept trial of ritux-
imab in ten patients with PAP. Results suggest that
rituximab may be an effective primary therapy in this
autoimmune disease [20]. The most striking clinical
finding from our PAP study of rituximab was the sig-
nificant improvement of oxygenation, the primary end-
point in 7/9 patients. Improvements were also noted
in total lung capacity, HRCT scans and transitional
dyspnea index. Importantly, neither total serum anti-
GM-CSF nor serum GM-CSF neutralizing capacity
were reduced following rituximab therapy. Reduction
of anti-GM-CSF levels in BAL fluid from the lung,
however, did correlate with improvement in PaO2 and
HRCT scans.
Mechanisms responsible for rituximab-mediated im-
provement in PAP disease activity are unclear. Our
previous studies of alveolar macrophages from
untreated PAP patients demonstrated dramatically
reduced PPARγ and ABCG1 expression that was re-
versible by either in vivo or in vitro GM-CSF treatment
[11,12]. In GM-CSF KO mice, in vivo administration of
lentivirus constructs containing either PPARγ or
ABCG1 reduced alveolar macrophage lipid accumula-
tion and upregulated PPARγ and ABCG1 [13,21]. Based
on such observations, we hypothesized that the clinical
improvement in rituximab-treated PAP patients might
be due to restoration of alveolar macrophage lipid
homeostasis associated with reduced GM-CSF autoanti-
body in the pulmonary compartment. In this paper, we
investigated this hypothesis by utilizing BAL samples
from the original cohort of PAP patients treated with
rituximab.
Methods
Study design
This study was a prospective, open-label, proof-of-
concept clinical trial of rituximab therapy in a group of
10 adult patients presenting with moderately symptom-
atic, idiopathic PAP as described in detail [20]. The
study was approved by the Institutional Review Board at
East Carolina University and informed consent was
obtained from all patients. The trial was registered at
clinicaltrials.gov (NCT00552461).
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Bronchoalveolar lavage (BAL) was carried out prior to
and 6 months after therapy as described [3,20,22]. Cytos-
pins were stained with Oil Red O to detect intracellular
neutral lipids and counterstained with Gill’s hematoxylin.
Oil Red O intensity was quantified using a modified scor-
ing system previously described [21,23]: +++ = strongly
positive; ++= positive; and + = weakly positive.Mice
Animal studies were conducted in conformity with Public
Health Service (PHS) Policy on humane care and use of
laboratory animals and were approved by the institutional
animal care committee. The GM-CSF KO mice were gen-
erated by Dr. Glenn Dranoff and have been previously
described [24]. Macrophage-specific PPARγ KO mice
have been previously described [25]. Animals studied were
age (8–12 week old) and gender-matched to wild type
C57Bl/6 controls obtained from Jackson Laboratory (Bar
Harbor, ME). BAL cells were obtained as described earlier
[25]. For all experiments 5–7 mice per group were used.RNA purification and analysis
Total cellular RNA was extracted by Lipid RNeasy proto-
col (Qiagen, Valencia, CA). Expression of mRNA was
determined by real time RT-PCR using the ABI Prism
7300 Detection System (TaqMan; Applied Biosystems,0.0
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Figure 1 Gene expression of lipid regulators is increased post-rituxim
RT-PCR in PAP patients before and 6 months post rituximab therapy. IncreaseFoster City, CA.) according to the manufacturer’s instruc-
tions. RNA specimens were analyzed in duplicate using
primer/probe sets for human PPARγ, ABCA1, ABCG1,
LPLA2 and the housekeeping gene, glyceraldehyde 3
phosphate dehydrogenase (GAPDH) (ABI) or murine
LPLA2 and GAPDH (ABI) as previously described [12].
Threshold cycle (CT) values for genes of interest were
normalized to GAPDH and used to calculate the relative
quantity of mRNA expression. Data were expressed as a
fold change in mRNA expression relative to control
values [26].
Cholesterol analysis
Cholesterol was measured in BAL fluid using the Abcam
(Cambridge, MA) Cholesterol Assay according to the
manufacturer’s instructions. Cholesterol content was
expressed as μg/μl of cholesterol.
Surfactant protein-A (SP-A) ELISA
SP-A was measured in BAL fluid with an ELISA kit (Bio-
vendor, Candler, NC) according to manufacturer’s
instructions. Total protein in BAL fluid was measured
by BCA protein assay (Pierce, Rockford, MA).
Statistical analysis
Parametric data are presented as means (±SEM) and non-
parametric data are presented as medians and ranges.0
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s are shown in: (A) PPARγ; (B) ABCG1; (C) ABCA1; and (D) LPLA2 (n= 6).
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Figure 3 Intracellular lipid staining is decreased post rituximab
therapy in PAP alveolar macrophages. Cytospin preparations of
alveolar macrophages were stained with Oil Red O and intensity was
quantified using a modified scoring previously described [21,23]; (++
+= strongly positive, ++= positive; + =weakly positive. A minimum
of 100 cells on cytospins from each of 5 paired pre and post therapy
samples were scored.
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Student’s t test. Nonparametric data were compared with
Wilcoxon test. P≤ 0.05 was considered significant.
Results
PPARγ and ABC lipid transporter expression levels are
elevated in alveolar macrophages from patients with PAP
Compared to pre-treatment levels, rituximab increased
PAP alveolar macrophage PPARγ and ABCG1 mRNA
expression by a mean of 2.8 and 5.3-fold respectively
(p ≤ 0.05, n = 6) (Figures 1A and B). Although, no signifi-
cant differences in mRNA expression levels of ABCA1
between healthy controls and PAP baseline alveolar
macrophages were found, levels became elevated after
rituximab, with a mean increase of 3.2 fold (p < 0.05,
n = 6) compared to pre-treatment (Figure 1C).
LPLA2 expression is deficient pre-treatment and elevated
by rituximab therapy
Examination of LPLA2, also indicated restorative effects
of rituximab. Mean LPLA2 levels were significantly
reduced compared to healthy controls in PAP patients
pre-treatment (p < 0.05, n = 6). Compared to pre-
treatment, however, LPLA2 mRNA expression signifi-
cantly increased post-rituximab by a mean of 2.8-fold
(p < 0.05) (Figure 1D).
LPLA2 expression is not deficient in macrophage-specific
PPARγ KO mice
Previous studies from our laboratory and others had
reported reduced expression of LPLA2 or PPARγ in
GM-CSF KO mice [12,14]. Since both of these genes
were deficient in pre-treatment PAP alveolar macro-
phages and upregulated by rituximab therapy, we soughtC57Bl/6 w/t PPARγ  KO  GM-CSF KO
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Figure 2 LPLA2 gene expression is decreased in alveolar
macrophages from GM-CSF KO mice as compared to wild type
C57Bl6. LPLA2 in macrophage-specific PPARγ KO mice was not
different from wild type (n = 6 mice per group).
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Figure 4 Extracellular cholesterol is increased in PAP
bronchoalveolar lavage fluid post rituximab therapy (n = 8).
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LPLA2 regulation. Therefore we investigated LPLA2
mRNA expression in BAL-derived cells from C57 wild-
type, GM-CSF KO, and macrophage-specific PPARγ
KO mice (Figure 2). As anticipated, GM-CSF KO ani-
mals exhibited significant LPLA2 mRNA deficiency
(−2.5-fold, p = 0.0069) compared to wild-type mice
(Figure 2). LPLA2 was not deficient, however, in
macrophage-specific PPARγ KO mice which were simi-
lar to wild-type (Figure 2). These data strongly suggest
that LPLA2 regulation is independent of PPARγ.
Intracellular lipid is reduced in PAP alveolar macrophages
Heavy (+++) intensity of Oil Red O staining character-
ized PAP alveolar macrophages prior to rituximab treat-
ment (Figure 3A). Post-treatment, alveolar macrophages0
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Figure 5 Extracellular surfactant protein A (A) and total protein (B) ar
SP-A; p = 0.02 protein).exhibited a shift toward less Oil Red O staining, indicat-
ing a reduction of intracellular neutral lipid (p = 0.005,
n = 6, Figure 3B).
Extracellular cholesterol is increased post-rituximab
Because cholesterol is a component of surfactant and
ABCG1 has been shown to increase cholesterol trans-
port [27] we measured cholesterol in the BAL fluid.
Rituximab increased levels of extracellular cholesterol
present in PAP BAL fluid post-treatment compared to
pre-treatment (p = 0.004, n = 8, Figure 4).
Surfactant protein-A (SP-A) is decreased in BAL fluid
following rituximab treatment
SP-A is a component is one of the four surfactant pro-
teins and has been reported to be elevated in BAL fluid± SEM
pre
post
t Number
7 8 9 10 mean 
8 9 10 mean ± SEM
Number
e decreased in PAP bronchoalveolar lavage fluid (n =8, p= 0.04
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were measured pre- and post-treatment and were found
to be decreased (Figure 5, n =8, p = 0.04 SP-A; p = 0.02
protein) indicating reduced extracellular accumulation
of surfactant protein.
Discussion
The findings presented here indicate that rituximab
treatment can have an impact upon restoration of alveo-
lar macrophage lipid homeostasis in PAP patients. Previ-
ous results indicated that rituximab treatment reduced
anti-GM-CSF autoantibody levels in the BAL fluids of
PAP patients studied here even though serum levels
were not significantly affected [20]. Moreover, rituximab
treatment was associated with clinical pulmonary im-
provement in terms of gas exchange (room air PaO2)
and radiographic evidence of disease (by high resolution
computed tomography of the chest). Data presented
here confirm the positive therapeutic effects of rituxi-
mab on PAP lung with respect to enhanced alveolar
macrophage functional activity and expression of lipid
regulatory genes, PPARγ, ABCG1, and LPLA2. Results
confirmed our initial hypothesis regarding the import-
ance of PPARγ and ABCG1 in maintaining alveolar
macrophage lipid metabolism. Compared to baseline,
both of these genes were significantly upregulated by
rituximab treatment. An unexpected finding was the de-
ficiency of LPLA2 in untreated PAP patients, a situation
that was significantly reversed by rituximab therapy. Our
data are the first to note deficient LPLA2 in alveolar
macrophages of untreated PAP patients and the upregu-
lation of LPLA2 after rituximab therapy.
As mentioned previously in this paper, LPLA2 has also
been found to be deficient in GM-CSF null mice [14].
LPLA2 activity was restored in bi-transgenic mice
in vivo by expression of GM-CSF in type II alveolar epi-
thelial cells under control of a surfactant protein C pro-
moter [14]. Investigation of LPLA2 in THP-1 myeloid
cells also indicated no stimulation by GM-CSF or the
PPARγ ligand, Troglitazone [15].
Results of our supplemental animal studies are the first
to indicate that LPLA2 is not deficient in macrophage-
specific PPARγ KO mice. Thus LPLA2 deficiency in PAP
does not appear to involve PPARγ although RXR is part
of the PPARγ heterodimer. While these findings indicate
distinct regulatory pathways for ABCG1 and LPLA2, fur-
ther studies are necessary to establish the mechanisms
by which GM-CSF corrects LPLA2 deficiency in PAP.
In summary, data indicate that clinical improvement
post-rituximab treatment in a previously described co-
hort of PAP patients is associated with improved lipid
homeostasis in alveolar macrophages from the same
patients. Findings also indicate that reconstruction of
lipid homeostasis in PAP alveolar macrophages is anintricate process requiring upregulation of the transcrip-
tion factor PPARγ, lipid transporter ABCG1, and the sur-
factant catabolic enzyme, LPLA2. Although PPARγ
dependence of ABCG1 has been established by studies in
PAP and in GM-CSF KO mice [12,13,21], mechanisms
regulating LPLA2 remain to be explored. Nevertheless,
restoration of biologically active GM-CSF via rituximab
therapy appears to be a successful means for improving
lipid homeostasis in PAP alveolar macrophages.
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